Research Topics
Species | Gregory CairncrossSummaryAffiliation: University of Calgary Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Imaging molecular signatures in oligodendrogliomaJ Gregory Cairncross
Department of Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
Clin Cancer Res 10:7109-11. 2004
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402Gregory Cairncross
Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9
J Clin Oncol 31:337-43. 2013..Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown...- Gliomas with 1p/19q codeletion: a.k.a. oligodendrogliomaGregory Cairncross
Department of Clinical Neurosciences and Hotchkiss Brain, Institute, University of Calgary, Calgary, Alberta, Canada
Cancer J 14:352-7. 2008.... 
Sensitivity to temozolomide in brain tumor initiating cellsMichael D Blough
Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada
Neuro Oncol 12:756-60. 2010..BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision...- Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Gregory Cairncross
University of Calgary, Calgary, Alberta, Canada E mail
J Clin Oncol 24:2707-14. 2006..Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss... - Leptomeningeal disease from oligodendroglioma: clinical and molecular analysisGloria Roldan
Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, University of Calgary, Calgary, Alberta Canada
Can J Neurol Sci 35:204-9. 2008..A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas... - Methylation status of MGMT gene promoter in meningiomasPaula de Robles
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
Cancer Genet Cytogenet 187:25-7. 2008..None of the meningiomas in our series showed MGMT gene promoter methylation. Based on these data, we conclude that there is no biological rational to suggest that TMZ might have significant anti-meningioma activity... - Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996Gloria Roldan
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
Can J Neurol Sci 35:210-5. 2008..Collins' Law dictates that 'cure' of a child with a tumor occurs after a period that includes the child's age at diagnosis plus 9 months... - The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendrogliomaRobert Brown
Department of Electrical and Computer Engineering, University of Calgary, Calgary, Alberta, Canada
Clin Cancer Res 14:2357-62. 2008..Some patients with low-grade glioma have extraordinarily long survival times; current, early treatment does not prolong their lives. For this reason, therapies that sometimes have neurologic side effects are often deferred intentionally... - A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomasPeter Forsyth
Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Mol Ther 16:627-32. 2008..Median TTP was 4.3 weeks (range, 2.6-39). An MTD was not reached. The intratumoral administration of the genetically unmodified reovirus was well tolerated using these doses and schedule, in patients with recurrent MG... - Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials groupMarc Webster
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Invest New Drugs 23:591-6. 2005..8-9.2) with progressive disease in the remainder.CONCLUSION: Despite promising preclinical data, SarCNU caused pulmonary toxicity in patients with recurrent malignant glioma and we plan no further studies in this indication... - Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?Donna Senger
Department of Oncology and Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta
Cancer J 9:214-21. 2003..We conclude by suggesting a translational research strategy that is aimed at uncovering the molecular signatures of long survivorship... - Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogensJohn J P Kelly
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
Stem Cells 27:1722-33. 2009..This novel experimental system will permit the elucidation of additional constitutively activated mechanisms that promote GBM BTSC survival, self-renewal, and proliferation... - An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imagingSylvia Drabycz
Department of Electrical and Computer Engineering, University of Calgary, Alberta, Canada
Neuroimage 49:1398-405. 2010.... - Population-based study of pseudoprogression after chemoradiotherapy in GBMGloria B Roldán
Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Can J Neurol Sci 36:617-22. 2009..Little is known about the natural history of radiographic pseudoprogression... - Predicting MGMT methylation status of glioblastomas from MRI textureIlya Levner
Department of Radiology, University of Calgary, Alberta, Canada
Med Image Comput Comput Assist Interv 12:522-30. 2009..Blinded classification of MGMT promoter methylation status reached an average accuracy of 87.7%, indicating that the proposed technique is accurate enough for clinical use... - Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experienceShelly Lwu
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
J Neurooncol 96:403-8. 2010..Increased awareness of practice guidelines may help modify AED prescription patterns in malignant glioma patients... - Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"Hikaru Sasaki
Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, USA
J Neuropathol Exp Neurol 61:58-63. 2002..As a result, such objective molecular genetic analyses should be incorporated into patient management and into clinical trials of low-grade diffuse gliomas... - High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-upLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neuro Oncol 8:183-8. 2006..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia... - The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and powerYi Li
Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Biometrics 58:232-6. 2002..Further, there may be a substantial loss of power in the presence of the frailty with or without an interaction with treatment... - High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendrogliomaLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
J Neurooncol 65:127-34. 2003.... - Imaging correlates of molecular signatures in oligodendrogliomasJoseph F Megyesi
Department of Clinical Neurological Sciences, University of Western Ontario and London Regional Cancer Centre, London, Ontario, Canada
Clin Cancer Res 10:4303-6. 2004..These data encourage prospective evaluation of molecular alterations and magnetic resonance imaging characteristics of glial neoplasms... - MGMT gene silencing and benefit from temozolomide in glioblastomaMonika E Hegi
Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
N Engl J Med 352:997-1003. 2005.... - Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaRoger Stupp
Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
N Engl J Med 352:987-96. 2005..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety... - Survey of treatment recommendations for anaplastic oligodendrogliomaLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neuro Oncol 9:314-8. 2007.... - Glioma therapies: how to tell which work?James R Perry
J Clin Oncol 21:3547-9. 2003 - Recent developments in the molecular characterization and treatment of oligodendroglial tumorsMartin van den Bent
Department of Neuro-Oncology, Dr. Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
Neuro Oncol 5:128-38. 2003..Further studies are needed to confirm the efficacy and safety profile of temozolomide and to determine the optimal dose and schedule for treating ODs... - Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trialWarren P Mason
Princess Margaret Hospital, Toronto, Ontario, Canada
Nat Clin Pract Neurol 1:88-95. 2005.... - Gene expression-based classification of malignant gliomas correlates better with survival than histological classificationCatherine L Nutt
Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 63:1602-7. 2003..These data suggest that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology... - Influence of unrecognized molecular heterogeneity on randomized clinical trialsRebecca A Betensky
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
J Clin Oncol 20:2495-9. 2002..Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes... - Ki-67: a prognostic factor for low-grade glioma?Barbara J Fisher
Department of Radiation Oncology, London Regional Cancer Centre and University of Western Ontario, London, Ontario, Canada
Int J Radiat Oncol Biol Phys 52:996-1001. 2002..Immunohistochemical techniques were used to detect the expression of Ki-67, a nuclear proliferation marker, in 180 low-grade glioma tumor specimens to determine whether Ki-67 is a prognostic predictor of survival or tumor recurrence... - DMBT1 polymorphisms: relationship to malignant glioma tumorigenesisHikaru Sasaki
Molecular Neuro Oncology and Pathology Laboratories, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
Cancer Res 62:1790-6. 2002..These data suggest that DMBT1 polymorphisms are not likely primary targets of 10q loss in malignant gliomas and do not support a major role for DMBT1 in gliomagenesis... - Analysis of a molecular genetic neuro-oncology study with partially biased selectionRebecca A Betensky
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
Biostatistics 4:167-78. 2003..Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients... - Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomasWarren P Mason
Department of Medicine, The University of Toronto, Toronto, Ontario, Canada
Neurology 71:365-73. 2008..Time will tell whether these new agents can be successfully introduced into the clinical arena. In the meantime, the molecular characteristics of gliomas are being used to select patients for both randomized trials and phase II studies... - Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three casesChristopher J Watling
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada
J Neurosurg 97:224-6. 2002..Acetazolamide, an orally administered carbonic anhydrase inhibitor, appears to be a specific and effective therapy for this uncommon neurological disorder... - Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastomaAnastasia Murat
Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
J Clin Oncol 26:3015-24. 2008..Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide... - Toxicity from chemoradiotherapy in older patients with glioblastoma multiformeAngelique E Sijben
Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
J Neurooncol 89:97-103. 2008..Elderly patients have glioblastomas (GBM) that are aggressive and poorly responsive to treatment. They are also prone to the side effects of treatment of GBM... - Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402Caterina Giannini
Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Brain Pathol 18:360-9. 2008..3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival... - Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomideG Wei Xu
Department of Oncology, University of Western Ontario, London, Ontario
Int J Cancer 116:187-92. 2005.... - Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia
EORTC Data Centre, Brussels, Belgium
Lancet Oncol 9:29-38. 2008.... - Adjuvant chemotherapy for adults with malignant glioma: a systematic reviewJames Perry
Odette Cancer Centre, Sunnybrook Health Sciences Centre Toronto, Ontario, Canada
Can J Neurol Sci 34:402-10. 2007..This systematic review examines the role of chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma... - Tests of association under misclassification: application to histological sampling in oncologyRebecca A Betensky
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA
Stat Med 26:4808-16. 2007..In this study, calcification, a feature related to the imaging parameters, was potentially misclassified as not present... - Changing paradigms--an update on the multidisciplinary management of malignant gliomaRoger Stupp
Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
Oncologist 11:165-80. 2006..This review summarizes recent developments, focusing on the clinical management of patients in daily neuro-oncology practice...